HENGRUI PHARMA Shares Climb Over 5% Following Robust Q1 Earnings Report

Stock News04-23

HENGRUI PHARMA (01276) saw its shares rise more than 5% after the release of its financial results. At the time of writing, the stock was up 3.22%, trading at HKD 68.85, with a turnover of HKD 135 million.

On April 22, the company announced its financial performance for the first quarter of 2026. The group reported revenue of RMB 8.141 billion, representing a year-on-year increase of 12.98%. Net profit attributable to shareholders reached RMB 2.282 billion, up 21.78% compared to the same period last year. Basic earnings per share were RMB 0.34.

During the first quarter of 2026, revenue from innovative drug sales amounted to RMB 4.526 billion, a significant increase of 25.75% year-on-year. This segment accounted for 61.69% of total drug sales revenue. Within innovative drug sales, revenue from anti-tumor products was RMB 3.313 billion, up 11.63% year-on-year, making up 73.20% of total innovative drug sales. Revenue from non-oncology products reached RMB 1.213 billion, surging 92.13% year-on-year and accounting for 26.80% of innovative drug sales.

With the continued approval of new products and new indications, coupled with the gradual inclusion of already reimbursed innovative drugs into hospital formularies, the company aims to achieve full-year innovative drug sales growth exceeding 30%. Revenue from out-licensing of innovative drugs during the reporting period was confirmed at RMB 787 million, primarily attributable to income recognized from GSK based on the completion progress of performance obligations.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1180400767?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-23 09:47","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1180400767","market":"other","top_or_hot":-1,"title":"HENGRUI PHARMA Shares Climb Over 5% Following Robust Q1 Earnings Report","media":"Stock News","content":"<p>HENGRUI PHARMA (01276) saw its shares rise more than 5% after the release of its financial results. At the time of writing, the stock was up 3.22%, trading at HKD 68.85, with a turnover of HKD 135 million.</p>\n<p>On April 22, the company announced its financial performance for the first quarter of 2026. The group reported revenue of RMB 8.141 billion, representing a year-on-year increase of 12.98%. Net profit attributable to shareholders reached RMB 2.282 billion, up 21.78% compared to the same period last year. Basic earnings per share were RMB 0.34.</p>\n<p>During the first quarter of 2026, revenue from innovative drug sales amounted to RMB 4.526 billion, a significant increase of 25.75% year-on-year. This segment accounted for 61.69% of total drug sales revenue. Within innovative drug sales, revenue from anti-tumor products was RMB 3.313 billion, up 11.63% year-on-year, making up 73.20% of total innovative drug sales. Revenue from non-oncology products reached RMB 1.213 billion, surging 92.13% year-on-year and accounting for 26.80% of innovative drug sales.</p>\n<p>With the continued approval of new products and new indications, coupled with the gradual inclusion of already reimbursed innovative drugs into hospital formularies, the company aims to achieve full-year innovative drug sales growth exceeding 30%. Revenue from out-licensing of innovative drugs during the reporting period was confirmed at RMB 787 million, primarily attributable to income recognized from GSK based on the completion progress of performance obligations.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>HENGRUI PHARMA Shares Climb Over 5% Following Robust Q1 Earnings Report</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHENGRUI PHARMA Shares Climb Over 5% Following Robust Q1 Earnings Report\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-04-23 09:47</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>HENGRUI PHARMA (01276) saw its shares rise more than 5% after the release of its financial results. At the time of writing, the stock was up 3.22%, trading at HKD 68.85, with a turnover of HKD 135 million.</p>\n<p>On April 22, the company announced its financial performance for the first quarter of 2026. The group reported revenue of RMB 8.141 billion, representing a year-on-year increase of 12.98%. Net profit attributable to shareholders reached RMB 2.282 billion, up 21.78% compared to the same period last year. Basic earnings per share were RMB 0.34.</p>\n<p>During the first quarter of 2026, revenue from innovative drug sales amounted to RMB 4.526 billion, a significant increase of 25.75% year-on-year. This segment accounted for 61.69% of total drug sales revenue. Within innovative drug sales, revenue from anti-tumor products was RMB 3.313 billion, up 11.63% year-on-year, making up 73.20% of total innovative drug sales. Revenue from non-oncology products reached RMB 1.213 billion, surging 92.13% year-on-year and accounting for 26.80% of innovative drug sales.</p>\n<p>With the continued approval of new products and new indications, coupled with the gradual inclusion of already reimbursed innovative drugs into hospital formularies, the company aims to achieve full-year innovative drug sales growth exceeding 30%. Revenue from out-licensing of innovative drugs during the reporting period was confirmed at RMB 787 million, primarily attributable to income recognized from GSK based on the completion progress of performance obligations.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1191","symbol_name":"制药","start_time":0,"source_url":"","article_id":"1180400767","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1180400767","pubTimestamp":1776908874,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"HENGRUI PHARMA (01276) saw its shares rise more than 5% after the release of its financial results. At the time of writing, the stock was up 3.22%, trading at HKD 68.85, with a turnover of HKD 135...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"600276":"恒瑞医药","BK1191":"制药","01276":"恒瑞医药","LU0405327494.USD":"ALLSPRING CHINA A FOCUS \"I\" (USD) ACC","BK0060":"抗癌","LU2097828474.EUR":"AZ EQUITY CHINA \"A\" (EUR) ACC A","LU2148510915.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"R\" (USD) ACC","LU1146622755.USD":"安本中国A股股票基金A Acc","LU0359201885.HKD":"BGF CHINA \"A2\" (HKD) ACC","BK4585":"ETF&股票定投概念","LU1820825898.SGD":"Aberdeen Standard SICAV I - China A Share Equity A Acc SGD-H","BK0196":"行业龙头","LU1655091616.SGD":"JPMorgan Funds - China A-Share Opportunities A (acc) SGD","LU2289578879.USD":"ALLIANZ CHINA A OPPORTUNITIES \"AT\" (USD) ACC","VXUS":"国际股票ETF-Vanguard","LU1580142542.USD":"Blackrock Systematic China A-Share Opportunities A2 USD","LU0359201612.USD":"贝莱德中国基金A2","LU1328615791.USD":"FULLERTON LUX FUNDS - ALL CHINA EQUITIES \"I\" (USD) ACC","LU1997245177.USD":"安联神洲A股基金","LU2328871848.SGD":"Eastspring Investments - China A Shares Growth AS SGD","LU0359202008.SGD":"Blackrock China Fund A2 SGD-H","LU1064130708.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"I\" (USD) ACC","BK0239":"医药制造","LU1023057109.AUD":"BGF CHINA \"A2\" (AUDHDG) ACC","LU2580892789.USD":"FRANKLIN SEALAND CHINA A-SHARES \"A\" (USD) ACC","LU1969619763.USD":"EASTSPRING INV CHINA A SHARES GROWTH \"A\" (USD) ACC","LU0405327148.USD":"ALLSPRING CHINA A FOCUS \"A\" (USD) ACC","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","LU1255011170.USD":"JPM CHINA A-SHARE OPPORTUNITIES \"A\" (USD) ACC","LU1781817850.SGD":"Blackrock Systematic China A-Share Opportunities A2 SGD-H","LU2543165471.USD":"E FUND (HK) GLOBAL QUALITY GROWTH \"A\" (USD) ACC","LU2097828557.USD":"AZ EQUITY CHINA \"A\" (USD) ACC","LU2097828631.EUR":"AZ EQUITY CHINA \"A\" (EUR) ACC","BK0183":"MSCI概念","BK4588":"碎股","BK0188":"融资融券","LU1997245094.SGD":"安联神州A股基金AT Acc SGD","BK0012":"证金概念","LU2097828714.EUR":"AZ EQUITY CHINA \"BAZ\" (EUR) ACC","LU2580892862.HKD":"FRANKLIN SEALAND CHINA A-SHARES \"A\" (HKD) ACC","LU1064131003.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"A\" (USD) ACC","BK0028":"国家队","LU2097828805.USD":"AZ EQUITY CHINA \"A-AZ\" (USD) ACC","LU2495084118.USD":"ALLIANZ CHINA A-SHARES \"ATH\" (USDHDG) ACC","LU1997244956.HKD":"ALLIANZ CHINA A-SHARES \"AT\" (HKD) ACC A"},"translate_title":"恒瑞医药第一季度盈利报告强劲后股价上涨逾5%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600276":1,"01276":1,"VXUS":1},"content_text":"HENGRUI PHARMA (01276) saw its shares rise more than 5% after the release of its financial results. At the time of writing, the stock was up 3.22%, trading at HKD 68.85, with a turnover of HKD 135 million.\nOn April 22, the company announced its financial performance for the first quarter of 2026. The group reported revenue of RMB 8.141 billion, representing a year-on-year increase of 12.98%. Net profit attributable to shareholders reached RMB 2.282 billion, up 21.78% compared to the same period last year. Basic earnings per share were RMB 0.34.\nDuring the first quarter of 2026, revenue from innovative drug sales amounted to RMB 4.526 billion, a significant increase of 25.75% year-on-year. This segment accounted for 61.69% of total drug sales revenue. Within innovative drug sales, revenue from anti-tumor products was RMB 3.313 billion, up 11.63% year-on-year, making up 73.20% of total innovative drug sales. Revenue from non-oncology products reached RMB 1.213 billion, surging 92.13% year-on-year and accounting for 26.80% of innovative drug sales.\nWith the continued approval of new products and new indications, coupled with the gradual inclusion of already reimbursed innovative drugs into hospital formularies, the company aims to achieve full-year innovative drug sales growth exceeding 30%. Revenue from out-licensing of innovative drugs during the reporting period was confirmed at RMB 787 million, primarily attributable to income recognized from GSK based on the completion progress of performance obligations.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1180400767","isCrawlerRequest":true}